Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon‐like peptide‐1 receptor agonists

Autor: Thomas S J, Crabtree, Karen, Adamson, Hazel, Reid, Dennis, Barnes, Siva, Sivappriyan, Alex, Bickerton, Ian W, Gallen, Benjamin C T, Field, Iskandar, Idris, Robert E J, Ryder

Publikováno v: Diabetes, Obesity and Metabolism. 24:1398-1401

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor ago

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91f4bc4aa8b88cc84728109a389f334e
https://doi.org/10.1111/dom.14701

858-P: Predictors of HbA1c and Weight Response to Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) in the Association of British Clinical Diabetologist (ABCD) UK Nationwide Audit

Autor: THOMAS S.J. CRABTREE, ALISON GALLAGHER, SIVA SIVAPPRIYAN, KETAN DHATARIYA, RAJEEV P. RAGHAVAN, ALEX BICKERTON, JACKIE ELLIOTT, MELISSA L. CULL, GERRY RAYMAN, IAN W. GALLEN, ISKANDAR R. IDRIS, ROBERT E. RYDER

Publikováno v: Diabetes. 71

SGLT2i treatment is associated with weight and Hba1c reduction. Previous work has demonstrated clinical predictors of HbA1c and weight reduction with canagliflozin. We aim to analyse predictors of HbA1c and weight change across the class. Methods: Pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce65f288ecd0d9a8fab72ccc5100d889
https://doi.org/10.2337/db22-858-p

Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit

Autor: Ken Darzy, Thomas Sj Crabtree, Anurita Rohilla, Iskandar Idris, Abcd Canagliflozin Audit Contributors, Rajeev Raghavan, Alex Bickerton, Alison Evans, Peter H. Winocour, Robert E.J. Ryder, Mahender Yadagiri, Suzanne Phillips, Devesh K. Sennik

Publikováno v: British Journal of Diabetes. 20:113-116

Introduction: Canagliflozin was initially approved for use in the UK in March 2013. Randomised control trial evidence has demonstrated multiple beneficial effects. Many of these are present at initial follow-up and within 26 weeks of randomised contr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d8d8ea9105274ba697d46acfaba5417c
https://doi.org/10.15277/bjd.2020.258

Education at scale: Improvements in type 1 diabetes self-management following a massive open online course

Autor: Scott C. Mackenzie, Kirsten M. Cumming, Salma Mehar, Lyn Wilson, Scott G. Cunningham, Alex Bickerton, Deborah J. Wake

Publikováno v: Mackenzie, S, Cumming, K M, Mehar, S, Wilson, L, Cunningham, S G, Bickerton, A & Wake, D J 2022, ' Education at Scale : Improvements in Type 1 Diabetes Self-Management Following a Massive Open Online Course (MOOC) ', Diabetic Medicine, vol. 39, no. 8, e14842 . https://doi.org/10.1111/dme.14842

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a0fd3ded4fc986f5d6d78c1c0fd25b6
https://pubmed.ncbi.nlm.nih.gov/35426171

1110-P: Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 Inhibitors (SGLT2i)

Autor: Suzanne M. Phillips, Anurita Rohilla, Karen Adamson, Ian W. Gallen, Thozhukat Sathyapalan, Alex Bickerton, Devesh K. Sennik, Rajeev Raghavan, Alison Evans, Mahender Yadagiri, Harshal Deshmukh, Robert E. Ryder

Publikováno v: Diabetes. 69

Introduction: Alanine transaminase (ALT) is an important marker for Nonalcoholic Fatty Liver Disease (NAFLD), and its levels are reduced following treatment with SGLT2i. However, how raised ALT levels and hence NAFLD affects HbA1c response to SGLT2i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b92e62bda00a0669ce37597f5b147a4
https://doi.org/10.2337/db20-1110-p